The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index; none of the 14 sources its claims cite is checked for support yet.
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Open accessAbstract
The incidence of tuberculosis has been increasing substantially on a worldwide basis over the past decade, but no tuberculosis-specific drugs have been discovered in 40 years. We identified a diarylquinoline, R207910, that potently inhibits both drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro (minimum inhibitory concentration 0.06 mug/ml). In mice, R207910 exceeded the bactericidal activities of isoniazid and rifampin by at least 1 log unit. Substitution of drugs included in the World Health Organization's first-line tuberculosis treatment regimen (rifampin, isoniazid, and pyrazinamide) with R207910 accelerated bactericidal activity, leading to complete culture conversion after 2 months of treatment in some combinations. A single dose of R207910 inhibited mycobacterial growth for 1 week. Plasma levels associated with efficacy in mice were well tolerated in healthy human volunteers. Mutants selected in vitro suggest that the drug targets the proton pump of adenosine triphosphate (ATP) synthase.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 14 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“R207910 was extensively distributed to tissues, including lungs and spleen (Fig. 3A, table S4).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These average concentrations were greater than that achieving optimal activity in established infection in mice.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Low MICs were also found for other mycobacterial species, including Mycobacterium bovis, Mycobacterium kansasii and Mycobacterium ulcerans, as well as species naturally resistant to many other anti-TB agents and involved in opportunistic infections, such as Mycobacterium avium complex (MAC), Mycobacterium abscessus, Mycobacterium fortuitum and Mycobacterium marinum (Table 1).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At 25 mg/kg, the activity of R207910 was significantly better than at 12.5 mg/kg (P = 0.005).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The bactericidal activity obtained by the RHZ combination after 2 months of therapy was matched by the combinations JHZ and RJZ after just 1 month of therapy.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Importantly, at 12.5 and 25 mg/kg, R207910 was significantly more active (P = 0.005) than 25 mg/kg isoniazid, a drug known for its strong, early bactericidal activity (Fig. 4A).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, the susceptibility of R207910-resistant M. tuberculosis strains remained unchanged to other anti-TB agents, including isoniazid, rifampin, streptomycin, amikacin, ethambutol and moxifloxacin.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“To date, 20 molecules of the DARQ series have a minimum inhibitory concentration (MIC) below 0.5 µg/ml against M. tuberculosis H37Rv.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Data from a multiple-ascending-dose study have shown an increase (approximately by a factor of two) in AUC 0-24h from Day 1 to Day 14 of once-daily dosing at 50, 150 and 400 mg R207910, without substantial variation between subjects.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Plasma levels associated with efficacy in mice are well tolerated in healthy human volunteers.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclear
- Probably not a substantial claim. 3
- It may state two separate claims as one. 40
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The most active compound of the class, R207910, is a pure enantiomer with two chiral centers.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“No accumulation of R207910 was observed after five daily oral doses, indicating that slow redistribution from tissues contributed to the relatively long half-lives in plasma.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the second study, the good tolerability was maintained; only one subject withdrew from the study, because of a urinary tract infection (unrelated to R207910) after seven doses at 150 mg/day.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When added to the first-line triple TB therapy combination RHZ, 25 mg/kg R207910 (J) increased the drop in bacterial load in the lungs by 2 log 10 after 1 month of therapy compared with standard RHZ treatment regimen, and a further 1 log 10 drop after 2 months.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Maximum plasma concentrations (C max ) of 0.40-0.54µg/ml with a single 6.25 mg/kg/dose were achieved within 1 hour and 1.1-1.3µg/ml with a 25 mg/kg/dose within 2-4 hours.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The majority of adverse events reported (supporting online text), were considered possibly related to the study medication-placebo (seven of 18 subjects) or R207910 (20 of 36 subjects).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The AUC showed a better correlation with the dose than C max , reflecting limitations in rate of absorption at higher dosing regimens, as confirmed in a single-dose pharmacokinetic study comparing C max and AUC after 6.25, 25 and 100 mg/kg.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“This anti-mycobacterial-specific spectrum differs from that of isoniazid, which has very poor activity against MAC.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In studies using oral treatment of R207910 for 5 days per week for 4 weeks, starting the day after inoculation, the minimal dose of R207910 that prevented mortality in nonestablished infection was 1.5 mg/kg, and the minimal effective dose (MED) preventing gross lung lesions was 6.5 mg/kg.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Exposure of M. tuberculosis in log-phase growth to concentrations of R207910 at 10-fold MIC resulted in a 3 log 10 reduction in bacterial counts after 12 days, indicating that R207910 has bactericidal activity in vitro (table S2).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Complementation studies have verified that the mutant atpE gene is responsible for resistance to R207910, implying that the atpE gene product is the target of R207910 in mycobacteria.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The range of MICs for the international reference strain M. tuberculosis H37Rv and six fully antibiotic susceptible isolates was 0.03-0.120µg/ml (Table 1), versus 0.500 µg/ml for rifampin and 0.120 µg/ml for isoniazid (results not shown).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All 30 isolates of MDR-TB tested were susceptible to 0.100 µg/ml of R207910, and 17 (57%) were susceptible to 0.010 µg/ml of R207910 (Table 2).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Pharmacokinetic results from the single-ascending-dose study suggested that R207910 is well absorbed after single oral administration, and the peak concentration was reached at 5 hours (median value) post-dose.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“R207910 had much higher MICs for Corynebacterium and Helicobacter pylori (MIC 4.0 µg/ml), and especially for other organisms such as Gram-positive Nocardia, Streptococcus pneumoniae, Staphylococcus aureus and Enterococcus faecalis, or Gram-negative Escherichia coli and Haemophilus influenzae (table S1).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Half-lives ranged from 43.7 to 64 hours in plasma and 28.1 to 92 hours in tissues (table S4).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Substitution of drugs included in the World Health Organization's firstline tuberculosis treatment regimen (rifampin, isoniazid and pyrazinamide) with R207910 accelerates bactericidal activity, leading to complete culture conversion after 2 months of treatment in some combinations.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The DARQ R207910 is a member of a new chemical class of anti-mycobacterial agents and has an MIC equal to or lower than that of reference compounds.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A single dose of 50 mg/kg R207910 in the non-established infection murine model of TB infection resulted in a bacteriostatic effect (0.5 log 10 drop in bacterial count in the lungs), which lasted for 8 days-a similar effect to that of rifapentine (10 mg/kg) (Fig. 3B).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In established infection (treatment beginning 12-14 days after inoculation when bacterial load was 5.94 log 10 CFU), 25 mg/kg R207910 as monotherapy was at least as active as the triple combination therapy (rifampin [R] + isoniazid [H] + pyrazinamide [Z]), and more active than rifampin alone (Fig. 4B).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We identified a diarylquinoline, R207910, that potently inhibits both drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro (MIC 0.06 µg/ml).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean AUC 0-24h values were 7.91, 24 and 52 µg/hour/ml at steady state, corresponding to average concentrations of 0.33, 1.0 and 2.2 µg/ml across a dosing interval, with 50, 150 and 400 mg/day, respectively.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The pharmacokinetics of R207910 were linear up to the highest dose tested (700 mg); both C max and AUC increased proportionally with the administered dose.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The two point mutations identified (D32V for M. smegmatis and A63P for M. tuberculosis) are both in the membrane-spanning domain region of the protein.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Areas under the concentration-time curve (AUCs) ranged from 5.0 to 5.9 µg/hour/ml with a 6.25 mg/kg/dose and 18.5 to 19.4 µg/hour/ml with a 25 mg/kg/dose (table S4).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“From selection experiments, the proportion of resistant mutants that emerged was 5 x 10 -7 and 2 x 10 -8 at four-fold MIC, and 5 x 10 -8 and 1 x 10 -8 at eight-fold MIC for M. tuberculosis and M. smegmatis, respectively (8).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
What the sources say
- Not matchedcites [8] 8. Details of materials and methods and supporting online text are available as supporting material on Science Online.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Substitution of each of the three first-line drugs with R207910 resulted in a dramatic increase in potency, leading to complete culture conversion of the lungs in some animals after only 2 months of treatment.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“R207910 has potent early bactericidal activity in the nonestablished murine TB model, matching or exceeding that of isoniazid (Fig. 4A), which is consistent with in vitro observations pointing to a bactericidal activity.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interestingly, the bactericidal potency seen upon administration of a single dose of 100 mg/kg R207910 in vivo was similar to the effect seen upon continuous exposure of cultures to 0.6 µg/ml (or 10-fold the median MIC of the H37Rv strain) in vitro, giving a first indication of the pharmacodynamics of R207910.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, the minimal bactericidal dose was very close to the MED, a finding confirming timedependent, rather than concentration-dependent, activity of R207910 in vitro.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Data suggest that maintaining average plasma levels of 0.3 µg/ml/day across a dosing interval, which is achieved with a 100 mg/kg/week dose, is necessary to achieve optimal effect of monotherapy in mice infected with strain H37Rv.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The killing effect was not increased by higher concentrations of the compound, suggesting the killing was time-dependent rather than concentration-dependent.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Although current first-line anti-TB drug regimens can achieve more than 99% efficacy, this is often reduced because of drug resistance (5).”
What the sources say
- Not matchedcites [5] 5. R. J. O'Brien, P. P. Nunn, Am. J. Respir. Crit. Care Med. 163, 1055 (2001).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
- Not matched
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“Structurally and mechanistically, DARQs are very different from both fluoroquinolones (including methoxyquinolones) and other quinoline classes, including mefloquine and its analogs 4-methylquinolines and 4quinolylhydrazones (9-13).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
What the sources say
- Not matchedcites [9] 9. R. Jain, B. Vaitilingam, A. Nayyar, P. B. Palde, Bioorg. Med. Chem. Lett. 13, 1051 (2003).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [10] 10. C. M. Kunin, W. Y. Ellis, Antimicrob. Agents Chemother. 44, 848 (2000).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [11] 11. M. R. Barbachyn, S. J. Brickner, Patent (International Publication Number: WO 93/09103, International Publication Date: 13 May, 1993, International Application Number: PCT/US92/08267, International Filing Date: 1992).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [12] 12. L. Savini, L. Chiasserini, A. Gaeta, C. Pellerano, Bioorg. Med. Chem. 10, 2193 (2002). / www.sciencexpress.org /9 December 2004 / Page 4/ 10.1126/science.1106753
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [13] 13. S. Vangapandu, M. Jain, R. Jain, S. Kaur, P. P. Singh, Bioorg. Med. Chem. 12, 2501 (2004).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The long half-lives and consequently prolonged exposure are important factors determining the duration of activity in vivo and provide a rationale for less frequent dosing regimens.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A comparison of the sequences of ATP synthases of different bacteria and of eukaryotic ATP synthase provides a rationale for the specificity of the antibacterial spectrum and, to a lesser extent, the safety profile of R207910.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, the distinct target of R207910 means that there is no crossresistance with existing anti-TB drugs, and our studies verified it is as effective against MDR strains as it is against fully antibiotic-susceptible strains.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“Inhibition of ATP synthase function may lead to ATP depletion and imbalance in pH homeostasis, both contributing to decreased survival (15,16).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
What the sources say
- Not matchedcites [15] 15. M. Rao, T. L. Streur, F. E. Aldwell, G. M. Cook, Microbiology 147, 1017 (2001).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [16] 16. G. Deckers-Hebestreit, K. Altendorf, Annu. Rev. Microbiol. 50, 791 (1996).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These are all attributes that are valuable for treatment of chronic infections and they may also be important for the development of simpler dosing regimens.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✗ Checkable: fails✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“The extent of bacterial load, the most effective drug combinations and treatment duration needed for sterilization are all similar in mice and humans (17).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
What the sources say
- Not matchedcites [17] 17. E. L. Nuermberger et al., Am. J. Respir. Crit. Care Med. 169, 421 (2004).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
The paper relies on this without support.
No tuberculosis-specific drugs have been discovered in 40 years.
“Tuberculosis has been increasing significantly on a worldwide basis over the past decade, but no tuberculosisspecific drugs have been discovered in 40 years.”
The paper relies on this without support.
The murine TB model is predictive of human TB treatment outcomes.
“The extent of bacterial load, the most effective drug combinations and treatment duration needed for sterilization are all similar in mice and humans (17).”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TMC207 is bactericidal towards most species of mycobacteria (109), but is only bacteriostatic against M. avium (118) and M. smegmatis (Berney and Cook, unpublished data).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When mycobacterial cells (growing or non-growing) are treated with TMC207, time-dependent (not dose-dependent) killing is observed (109).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most promising compounds clinically, the diarylquinolines, have been shown to target the F1Fo-ATP synthase and inhibit ATP synthesis (109, 111, 112).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“M. smegmatis was used for the initial compound screening that identified diarylquinoline (later named Bedaquiline) as a specific inhibitor of mycobacterial ATP synthase in 2005, which ended a 40-year dearth in anti-TB drug discovery (147).”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [147]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, Bedaquiline, the first new TB drug in 40 years, was discovered through an M. smegmatis screen.”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [147]
Citations
Cites
Amino acid substitution matrices from protein blocks.
Henikoff, S., & Henikoff, J. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10915 · Cited by 6,218
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
Comparing the Means of Several Groups
Godfrey, K. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512053132305 · Cited by 740
Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis
Nuermberger, E. L., Yoshimatsu, T., Tyagi, S. K., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200310-1380oc · Cited by 315
Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis
Siddiqi, S. H., Libonati, J. P., & Middlebrook, G. (1981) · Journal of Clinical Microbiology · doi:10.1128/jcm.13.5.908-912.1981 · Cited by 242
The Need for New Drugs against Tuberculosis
O'BRIEN, R. J., & NUNN, P. P. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.5.2007122 · Cited by 221
THE F0F1-TYPE ATP SYNTHASES OF BACTERIA: Structure and Function of the F0 Complex
Deckers-Hebestreit, G., & Altendorf, K. (1996) · Annual Review of Microbiology · doi:10.1146/annurev.micro.50.1.791 · Cited by 195
Intracellular pH regulation by Mycobacterium smegmatis and Mycobacterium bovis BCG
Rao, M., Streur, T. L., Aldwell, F. E., & Cook, G. M. (2001) · Microbiology · doi:10.1099/00221287-147-4-1017 · Cited by 148
Synthesis and anti-tubercular evaluation of 4-quinolylhydrazones
Savini, L., Chiasserini, L., Gaeta, A., & Pellerano, C. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(02)00071-8 · Cited by 134
Flagged first, then by citations
Cited by
Sorted by citations
Items 1,201–1,300 of 2,159
Bown, L., Srivastava, S. K., Piercey, B. M., McIsaac, C. K., & Tahlan, K. (2017) · The Journal of Membrane Biology · doi:10.1007/s00232-017-9997-3 · Cited by 16
Kuok, K. I., Ng, P. C. I., Ji, X., et al. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.12.022 · Cited by 16
“BDQ is a first-in-class drug of diarylquinoline, by binding to the subunit c of ATP synthase, which is crucial for generating energy in mycobacteria, it suppresses mycobacterial energy metabolism (Andries and Guillemont, 2005; Haagsma et al., 2011).”
BackgroundRP-HPLC determination of lipophilicity in series of quinoline derivatives
Musioł, R., Jampílek, J., Podeszwa, B., et al. (2009) · Open Chemistry · doi:10.2478/s11532-009-0059-2 · Cited by 16
Park, H.-E., Lee, W., Shin, M., & Shin, S. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.703060 · Cited by 16
“Bedaquiline (BDQ) specifically disrupts intracellular ATP production in bacteria by inhibiting the activity of bacterial ATP synthase, resulting in depleted energy production (118, 119).”
BackgroundCai, Y.-P., Zhang, W., Lun, S., et al. (2022) · Molecules · doi:10.3390/molecules27092844 · Cited by 15
“In more than half a century, only three new anti-TB drugs, bedaquiline (1, Figure 1) [2], delamanid (2) [3], and pretomanid (3) [4], have entered the market.”
BackgroundCook, G. M., Hards, K., Dunn, E. A., Heikal, A., Nakatani, Y., Greening, C., Crick, D. C., Fontes, F. L., Pethe, K., Hasenoehrl, E., et al. (2017) · ASM Press eBooks · doi:10.1128/9781555819569.ch14 · Cited by 15
Top-Down Identification and Sequence Analysis of Small Membrane Proteins Using MALDI-MS/MS
Meier‐Credo, J., Preiß, L., Wüllenweber, I., Resemann, A., Nordmann, C., Zabret, J., Suckau, D., Michel, H., Nowaczyk, M. M., Meier, T. W., et al. (2022) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.2c00102 · Cited by 15
From drugs to targets: Reverse engineering the virtual screening process on a proteomic scale
Schottlender, G., Prieto, J. M., Palumbo, M. C., Castello, F. A., Serral, F., Sosa, E. J., Turjanski, A. G., Marti, M. A., & Porto, D. F. D. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.969983 · Cited by 15
“This technique has been, for example, successfully used to identify bedaquiline’s target in mycobacteria, which to everybody’s surprise turned out to be the ubiquitous ATP synthase (Andries et al., 2005; Kundu et al., 2016).”
MethodBriffotaux, J., Xu, Y., Huang, W., Hui, Z., Wang, X., Gicquel, B., & Liu, S. (2022) · Molecules · doi:10.3390/molecules27207130 · Cited by 16
Zhou, Y., Shao, M., Wang, W., Cheung, C., Wu, Y., Yu, H., Hu, X., Cook, G. M., Gong, H., & Lu, X. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114896 · Cited by 17
Targeting polyketide synthase 13 for the treatment of tuberculosis
Xia, F., Zhang, H., Yang, H., Zheng, M., Min, W., Sun, C., Yuan, K., & Yang, P. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115702 · Cited by 18
Therapeutic drug monitoring in tuberculosis
Sarkar, M. S., & Sarkar, J. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03749-8 · Cited by 15
“It inhibits mycobacterial adenosine triphosphate (ATP) synthase, thereby disrupting mycobacterial energy production [161].”
2-Aryl-Benzoimidazoles as Type II NADH Dehydrogenase Inhibitors of Mycobacterium tuberculosis
Saha, P., Sau, S., Kalia, N. P., & Sharma, D. K. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00710 · Cited by 16
Suman, P., Dayakar, C., Rajkumar, K., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.04.009 · Cited by 15
Rational design of drug-like compounds targeting Mycobacterium marinum MelF protein
Dharra, R., Talwar, S., Singh, Y., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183060 · Cited by 15
Rani, A., Viljoen, A. J., Sumanjit, et al. (2017) · ChemistrySelect · doi:10.1002/slct.201702220 · Cited by 15
Chandramohan, Y., Padmanaban, V., Bethunaickan, R., et al. (2019) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2019.06.013 · Cited by 15
A Multimethod, Multicountry Evaluation of Breakpoints for Bedaquiline Resistance Determination
Ismail, N. A., Aono, A., Borroni, E., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00479-20 · Cited by 15
“atpE (2) and the efflux pump regulator Rv0678 (12, 15, 16), which have been observed in clinical isolates (12, 17).”
Backgroundde Araújo, R. V., Santos, S. D. S., Sanches, L. M., Giarolla, J., Seoud, O. A. E., & Ferreira, E. I. (2020) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/0074-02760200229 · Cited by 15
“Bedaquiline (TMC-207) (Table II) is a diarylquinoline, inhibiting the proton pump of mycobacterial ATP synthase, leading to ATP depletion and an imbalance in pH homeostasis.(60) Bedaquiline, when added to an optimal treatment regimen for MDR-TB and XDR-TB, provided higher and earlier sputum culture conversion when com…”
BackgroundBacterial F-type ATP synthases follow a well-choreographed assembly pathway
Huu, K. V., Zangl, R., Hoffmann, J., Just, A., & Morgner, N. (2022) · Nature Communications · doi:10.1038/s41467-022-28828-1 · Cited by 15
“Recently, the F-type ATP synthase has been highlighted as a novel drug target against Mycobacterium tuberculosis[1,2] and the enzyme is gaining more and more interest as an attractive molecular target for the therapy of a variety of diseases (e.”
BackgroundThe reactions between [RuHCl(CO)(PPh3)3] and quinoline carboxylic acids
Małecki, J. G., Kruszyński, R., Tabak, D., et al. (2007) · Polyhedron · doi:10.1016/j.poly.2007.07.023 · Cited by 15
Ji, Y., & Lei, T. (2013) · Science Progress · doi:10.3184/003685013x13617194309028 · Cited by 15
Nagabushan, H., & Roopadevi, H. S. (2014) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.138772 · Cited by 15
Li, C., Lee, Y., & Chen, B. (2016) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2016.00124 · Cited by 15
“Another study reported that the molecule TMC207 targets heavy metal P-type ATPase including Rv0969 (CtpV) (Andries et al., 2005; Novoa-Aponte and Soto Ospina, 2014), which may mediate Mtb P-type ATPase activation and enhance the metal toxicity to eliminate Mtb during metal burst in both cell types.”
BackgroundBwalya, P., Yamaguchi, T., Mulundu, G., et al. (2017) · Tuberculosis · doi:10.1016/j.tube.2017.12.007 · Cited by 15
“continues to bear on treatment outcome in the hunt for novel anti-TB drugs [20][21][22].”
BackgroundTrenado-Uribe, M., Silva‐Miranda, M., Rivero-Cruz, J. F., et al. (2018) · Molecular Biology Reports · doi:10.1007/s11033-018-4424-0 · Cited by 15
Applications of Molecular Simulation in the Discovery of Antituberculosis Drugs: A Review
Hu, J., Wu, Z., Xie, T., Liu, X., Yan, X. H., Sun, X., Liu, W., Liang, L., He, G., Gan, Y., et al. (2019) · Protein and Peptide Letters · doi:10.2174/0929866526666190620145919 · Cited by 15
Design and Synthesis of Pyrano[3,2- b ]indolones Showing Antimycobacterial Activity
Monakhova, N., Korduláková, J., Vocat, A., Egorova, A., Lepioshkin, A., Salina, E. G., Nosek, J., Repková, E., Zemanová, J., Jurdáková, H., et al. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00622 · Cited by 15
The pursuit of mechanism of action: uncovering drug complexity in TB drug discovery
Yuan, T., Werman, J. M., & Sampson, N. S. (2021) · RSC Chemical Biology · doi:10.1039/d0cb00226g · Cited by 16
Tuberculosis: current scenario, drug targets, and future prospects
Bose, P., Harit, A. K., Das, R., Sau, S., Iyer, A. K., & Kashaw, S. K. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02691-5 · Cited by 18
Drug discovery in tuberculosis: a molecular approach.
Mitra, P. (2012) · PubMed · Cited by 15
Impact of non-profit organizations on drug discovery: opportunities, gaps, solutions
Matter, A., & Keller, T. H. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.02.005 · Cited by 15
Abbadi, B. L., Rodrigues-Junior, V. S., Dadda, A. D. S., Pissinate, K., Villela, A. D., Campos, M. M., Lopes, L. G. D. F., Bizarro, C. V., Machado, P., Sousa, E. H. S., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00880 · Cited by 15
“, 2014), such as bedaquiline (Andries et al., 2005), pyridomycin (Hartkoorn et al.”
BackgroundMethodThe Prospective Synergy of Antitubercular Drugs With NAD Biosynthesis Inhibitors
Rohde, K. H., & Sorci, L. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.634640 · Cited by 14
A simple assay for inhibitors of mycobacterial oxidative phosphorylation
Harden, S. A., Courbon, G. M., Liang, Y., Kim, A. S., & Rubinstein, J. L. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105483 · Cited by 18
“Bedaquiline inhibits mycobacterial ATP synthase by binding with low af fi nity to the ring of c subunits in the enzyme ’ s rotor subcomplex (14, 15), with two high-af fi nity binding sites at the interface of subunit a with the c ring (16).”
BackgroundMehta, K., Balazki, P., van der Graaf, P. H., Guo, T., & van Hasselt, J. G. C. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01363-6 · Cited by 14
Bedaquiline Monotherapy for Multibacillary Leprosy
Barreto, J. A., Rosa, P. S., Adams, L. B., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312928 · Cited by 14
Self-citationHu, L., Gui, W., Liu, Z., et al. (2014) · RSC Advances · doi:10.1039/c4ra05670a · Cited by 14
Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis
Coulibaly, S., Cimino, M., Ouattara, M., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112821 · Cited by 14
“treatment of MDR-TB, bedaquiline (also named SIRTURO or TMC207).[3] This new drug”
MethodZeng, S., Zhang, J., Sun, M., Zhang, X., Cook, G. M., & Zhang, T. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00956-21 · Cited by 13
“tuberculosis electron transport chain (ETC) has emerged as a target for new anti-TB agents, leading to the discovery of FoF1 ATP synthase inhibitors (3) and of cytochrome bc1 inhibitors, including Telacebec (previously known as Q203) (4), TB47 (5), and lansoprazole (6).”
Background3‐Aryl‐substituted imidazo[1,2‐a]pyridines as antituberculosis agents
Karale, U. B., Shinde, A. U., Babar, D. A., et al. (2021) · Archiv der Pharmazie · doi:10.1002/ardp.202000419 · Cited by 14
New Drugs and Regimens for Tuberculosis Disease Treatment in Children and Adolescents
Garcia‐Prats, A. J., Starke, J. R., Waning, B., Kaiser, B. L., & Seddon, J. A. (2022) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piac047 · Cited by 17
In vitro and Intracellular Antibacterial Activity of Sudapyridine (WX-081) Against Tuberculosis
Xiao, H., Yu, X., Shang, Y., et al. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s390187 · Cited by 14
Filtration Improves the Performance of a High-Throughput Screen for Anti-Mycobacterial Compounds
Cheng, N., Porter, M. A., Frick, L., Nguyen, Y., Hayden, J., Young, E., Braunstein, M., Hull-Ryde, E. A., & Janzen, W. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096348 · Cited by 14
“smegmatis, was used to assay several thousand compounds [9].”
MethodLiu, G. E. (2009) · Recent Patents on Food Nutrition & Agriculture · doi:10.2174/2212798410901010075 · Cited by 18
“Several studies using the 454 platform have been published on pathogens such as HIV viruses [17] and Mycobacterium tuberculosis [18].”
Bedaquiline: a new weapon against MDR and XDR-TB
Singh, H., Natt, N. K., Garewal, N., et al. (2013) · International Journal of Basic & Clinical Pharmacology · doi:10.5455/2319-2003.ijbcp20130301 · Cited by 14
Bedaquiline: A New Hope to Treat Multi-Drug Resistant Tuberculosis
Patel, R. V., Riyaz, S., & Park, S. J. (2014) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026614666140929114822 · Cited by 14
Douša, M., Reitmajer, J., Lustig, P., et al. (2016) · Journal of Chromatographic Science · doi:10.1093/chromsci/bmw050 · Cited by 14
An Experimental Model for the Rapid Screening of Compounds with Potential Use Against Mycobacteria
Costa, S. S., Lopes, E., Azzali, E., Machado, D., Coelho, T. S., da Silva, P. E. A., Viveiros, M., Pieroni, M., & Couto, I. (2016) · Assay and Drug Development Technologies · doi:10.1089/adt.2016.752 · Cited by 14
Anti-tubercular drug discovery: in silico implications and challenges
Mehra, R., Khan, I. A., & Nargotra, A. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.03.028 · Cited by 14
Clinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis
Kwon, Y. S. (2017) · Chonnam Medical Journal · doi:10.4068/cmj.2017.53.2.103 · Cited by 14
“Bedaquiline resistance is caused by mutations in atpE encoding a part of the F0 subunit of ATP synthase which is the target of the drug and rv0678.(19,28) Mutation in rv0678 causes transcriptional upregulation of mmpS5 and mmpL5 resulting in cross-resistance to clofazimine through the activation of MmpL proteins which…”
BackgroundWang, G., Dong, W., Lu, H., Lu, W., Feng, J., Wang, X., Chen, H., Liu, M., & Tan, C. (2019) · Molecules · doi:10.3390/molecules25010038 · Cited by 15
“Interestingly, as the latest anti-tuberculosis drug, a lead compound diarylquinoline (TMC207), a precursor of bedaquiline, has been discovered in recent decades by using a similar approach [8].”
BackgroundSviriaeva, E. N., Manimekalai, M. S. S., Grüber, G., et al. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00449 · Cited by 14
Antimicrobial Prodrug Activation by the Staphylococcal Glyoxalase GloB
Mikati, M. O., Miller, J. J., Osbourn, D. M., Barekatain, Y., Ghebremichael, N., Shah, I. T., Burnham, C. D., Heidel, K. M., Yan, V. C., Müller, F. L., et al. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00582 · Cited by 13
Bioenergetic Heterogeneity in Mycobacterium tuberculosis Residing in Different Subcellular Niches
Akela, A. K., & Kumar, A. (2021) · mBio · doi:10.1128/mbio.01088-21 · Cited by 18
“licating state, a recently identified inhibitor of ATP synthase, bedaquiline (BDQ) (12), is”
BackgroundIn Vitro Susceptibility of Mycobacterium tuberculosis Clinical Isolates to Garenoxacin and DA-7867
Cabrera, L. V., Castro‐Garza, J., Rendón, A., Ocampo‐Candiani, J., Welsh, O., Choi, S. H., Blackwood, K. S., & Molina-Torres, C. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.10.4351-4353.2005 · Cited by 14
“tuberculosis isolates, have been observed with a newly developed drug, an ATP synthase inhibitor, R207910 (2).”
BackgroundInfluentialTuberculosis in transplant recipients: diagnostic and therapeutic dilemmas
Subramanian, A. K., & Nuermberger, E. L. (2008) · Transplant Infectious Disease · doi:10.1111/j.1399-3062.2008.00332.x · Cited by 14
“ISSN 1398-2273 229 evaluation in clinical trials to improve treatment of MDRTB (10, 11).”
BackgroundMa, Z., Ginsberg, A. M., & Spigelman, M. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00224-8 · Cited by 20
Chapter 5 The 454 Life Sciences Picoliter Sequencing System
Margulies, M., Jarvie, T. P., Knight, J., et al. (2007) · Perspectives in bioanalysis · doi:10.1016/s1871-0069(06)02005-2 · Cited by 14
Candida albicans’ inorganic phosphate transport and evolutionary adaptation to phosphate scarcity
Acosta-Zaldívar, M., Qi, W., Mishra, A., Roy, U., King, W. R., Li, Y., Patton-Vogt, J., Anderson, M. Z., & Köhler, J. R. (2024) · PLOS Genetics · doi:10.1371/journal.pgen.1011156 · Cited by 14
“In vitro evolution and whole genome analysis has been used in other pathogens for the characterization of drug responses [45–49] and in Candida species for analysis of drug resistance development [50–54].”
MethodSous, C., Frigui, W., Pawlik, A., Sayes, F., Ma, L., Cokelaer, T., & Brosch, R. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.04126-23 · Cited by 14
The Crosstalk Between HIV-TB Co-Infection and Associated Resistance in the Indian Population
Jadhav, S., Nair, A., Mahajan, P., & Nema, V. (2024) · Venereology · doi:10.3390/venereology3040015 · Cited by 14
“Collaborative efforts between healthcare providers, researchers, policymakers, and community stakeholders are indispensable for developing evidence-based interventions and achieving sustainable improvements in public health outcomes.”
Scaffold Hopping in Tuberculosis Drug Discovery: Principles, Applications, and Case Studies
Kovar, O., Kufa, M., Finger, V., Soukup, O., Krátký, M., Torruellas, C., Roh, J., & Korábečný, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01100 · Cited by 14
Liang, L., Lin, D., Chen, Y., Li, J., Liang, W., Zhao, H., Luo, W., Tian, G., & Feng, S. (2022) · mSystems · doi:10.1128/msystems.00209-22 · Cited by 14
“For example, bedaquiline (BDQ) (9), Q203 (10), SQ109 (11), and delamanid (12) are new suppressors targeting a range of enzymes or cofactors responsible for the mycobacterial electron transport chain that stop oxidative phosphorylation and block energy generation in mycobacteria.”
BackgroundMcNeil, M. B., Cheung, C., Waller, N. J. E., Adolph, C., Chapman, C. L., Seeto, N. E. J., Jowsey, W. J., Li, Z., Hameed, H. M. A., Zhang, T., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.980844 · Cited by 12
Xu, Y., Ehrt, S., Schnappinger, D., & Beites, T. (2023) · mBio · doi:10.1128/mbio.01045-23 · Cited by 16
“However, one could make 228 a case for such an endeavor given the successful identification of inhibitors to Mtb enzymes that 229 have homologues in humans, like bedaquiline (2) (ATP synthase) and Q203 (cytochrome bc1 230 complex) (19).”
BackgroundPotential of Mycobacterium tuberculosis Type II NADH-Dehydrogenase in Antitubercular Drug Discovery
Saha, P., Kumar, M., & Sharma, D. K. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c01005 · Cited by 13
Next-generation antimicrobials: from chemical biology to first-in-class drugs
Ang, M. L. T., Murima, P., & Pethe, K. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0645-0 · Cited by 13
“2007), whilst exploiting cutting-edge technologies to accelerate the discovery and development of novel antimicrobials (Andries et al. 2005; Makarov et al. 2009; Rottmann et al. 2010; Pethe et al. 2013; Ling et al. 2015).”
BackgroundInfluentialMachura, B., Wolff, M. J., Kowalczyk, W., et al. (2011) · Polyhedron · doi:10.1016/j.poly.2011.11.051 · Cited by 13
Pieroni, M., Lilienkampf, A., Wang, Y., Wan, B., Cho, S., Franzblau, S. G., & Kozikowski, A. P. (2010) · ChemMedChem · doi:10.1002/cmdc.201000169 · Cited by 13
Harris, P. W. R., Cook, G. M., Leung, I. K. H., et al. (2016) · Australian Journal of Chemistry · doi:10.1071/ch16499 · Cited by 13
Singh, A., Yadav, P., Karaulia, P., et al. (2017) · Future Microbiology · doi:10.2217/fmb-2017-0054 · Cited by 13
Kapadiya, K. M., Jadeja, Y. S., Banik, A., et al. (2018) · Folia Medica · doi:10.2478/folmed-2018-0034 · Cited by 13
“6-fl ourochromane-2-carboxilic acid (1), 3,4,5-Trimethoxyaniline (2), Various aromatic aldehydes (3a-o) and tert-butyl isocyanide (4), gives racemic products in analytically comparable yield (5a-o) (Reaction Scheme 1).”
BackgroundAdvances in Drug Discovery and Development for Pediatric Tuberculosis
Hoagland, D. T., Zhao, Y., & Lee, R. E., Jr. (2016) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666150722101723 · Cited by 15
Marigot-Outtandy, D., & Perronne, C. (2009) · Réanimation · doi:10.1016/j.reaurg.2009.03.007 · Cited by 13
Asymmetric Synthesis and Absolute Configuration Assignment of a New Type of Bedaquiline Analogue
Qiao, C.-J., Wang, X., Xie, F., Zhong, W., & Li, S. (2015) · Molecules · doi:10.3390/molecules201219846 · Cited by 14
“tuberculosis [4], was approved by the FDA to specifically treat MDR-TB.”
BackgroundAdvances in basic and translational tuberculosis research
Geadas, C., Stoszek, S., Sherman, D. R., Andrade, B. B., Srinivasan, S., HAMILTON, C. D., & Ellner, J. J. (2016) · Tuberculosis · doi:10.1016/j.tube.2016.11.006 · Cited by 13
“Compared to standard treatment regimens, 449 diarylquinolines (bedaquiline) accelerated bactericidal activity and led to complete culture conversion in 2 450 months.[40] After proving efficacious in human volunteers, and despite remaining questions regarding its 451 safety, the class received approval from the Food an…”
BackgroundJung, I., Ha, N., Kim, A.-R., et al. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.03.126 · Cited by 13
News on therapeutic management of MDR-tuberculosis: a literature review
Barthod, L., Lopez, J. G., Curti, C., Bornet, C., Roche, M., Montana, M., & Vanelle, P. (2017) · Journal of Chemotherapy · doi:10.1080/1120009x.2017.1338845 · Cited by 14
Krah, A., Marzinek, J. K., & Bond, P. J. (2019) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2019.02.010 · Cited by 13
Radical coupling of β-ketoesters and amides promoted by Brønsted/Lewis acids
Zhu, J. L., Laws, S. W., Rourke, M. J., & Scheidt, K. A. (2020) · Green Synthesis and Catalysis · doi:10.1016/j.gresc.2020.06.003 · Cited by 13
Zhang, L., Zhang, J., Ren, B., et al. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-10842-2 · Cited by 13
“Despite the recent approval of two new drugs, bedaquiline (2012) (Andries et al. 2005) and delamanid (2014) (Matsumoto et al. 2006), there is still a rising need for novel anti-TB drugs due to the fact that acquired resistance has been observed in therapy process (Bloemberg et al. 2015).”
BackgroundDefining the 'survivasome' of Mycobacterium tuberculosis
Lamichhane, G., & Bishai, W. R. (2007) · Nature Medicine · doi:10.1038/nm0307-280 · Cited by 13
Attack on the Scourge of Tuberculosis: Patented Drug Targets
Vohra, R., Gupta, M., Chaturvedi, R., & Singh, Y. P. (2006) · Recent Patents on Anti-Infective Drug Discovery · doi:10.2174/157489106775244127 · Cited by 13
“The molecule is active against both drugsensitive and drug-resistant M. tuberculosis and it was suggested that the drug targets the proton pump of adenosine triphosphate (ATP) synthase [ 129 ].”
Porphyromonas gingivalis is highly sensitive to inhibitors of a proton-pumping ATPase
Sekiya, M., Shimoyama, Y., Ishikawa, T., Sasaki, M., Futai, M., & Nakanishi‐Matsui, M. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.03.066 · Cited by 13
Once-Weekly Treatment of Tuberculosis with the Diarylquinoline R207910: A Real Possibility
Nuermberger, E. L., & Mitchison, D. A. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200808-1333ed · Cited by 13
Joshi, R. S., Mandhane, P. G., Khan, W., et al. (2011) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.653 · Cited by 12
Isa, M. A., Abubakar, M. B., Mohammed, M. M., et al. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e08482 · Cited by 12
Dinner date: Neisseria gonorrhoeae central carbon metabolism and pathogenesis
Potter, A. D., & Criss, A. K. (2023) · Emerging Topics in Life Sciences · doi:10.1042/etls20220111 · Cited by 14
Fil, M., & Alibert, S. (2024) · BioMed · doi:10.3390/biomed4030018 · Cited by 14
“ATP synthase, targeted by bedaquiline, inhibits the mycobacterial ATP synthase, leading to energy depletion and bacterial death [8].”
BackgroundA unique F-type H+-ATPase from Streptococcus mutans: An active H+ pump at acidic pH
Sasaki, Y., Nogami, E., Maeda, M., et al. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.12.025 · Cited by 12
Gingras, H., Patron, K., Bhattacharya, A., Leprohon, P., & Ouellette, M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02381-18 · Cited by 12
“(D) RT-qPCR for monitoring the expression of the dpr gene (1), the dpr-dhfr cotranscript (2), and the dhfr gene (3) in S.”
BackgroundSalifu, E. Y., Agoni, C., Olotu, F. A., Dokurugu, Y. M., & Soliman, M. E. S. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28891 · Cited by 13
“This as well is a crucial machinery that has been recently identified as an attractive drug target against Mtb largely due to a significant variation in the regulatory mechanisms amongst bacterial and eukaryotic organisms.(3,19,62) Among the notable therapeutic agents that target F‐type ATP synthase is BDQ, a diarylqu…”
BackgroundInfluentialDewangan, R. P., Singh, M., Ilic, S., Tam, B., & Akabayov, B. (2021) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13925 · Cited by 12
Girardini, M., Ferlenghi, F., Annunziato, G., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114916 · Cited by 12
A novel approach to eradicate latent TB: Based on resuscitation promoting factors
Seidi, K., & Jahanban‐Esfahlan, R. (2013) · Journal of Medical Hypotheses and Ideas · doi:10.1016/j.jmhi.2013.04.002 · Cited by 12
Campen, R., Ackerley, D. F., Cook, G. M., & O’Toole, R. (2015) · Tuberculosis · doi:10.1016/j.tube.2015.03.012 · Cited by 12
“This approach was used in the identification of a molecular target of the diarylquinoline, Bedaquiline, as the ATP synthase C subunit gene atpE of Mycobacterium tuberculosis [16].”
MethodChemical biology and bacteria: not simply a matter of life or death
Hung, D. T., & Rubin, E. J. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.06.016 · Cited by 12
Synthesis and Investigation of Phthalazinones as Antitubercular Agents
Santoso, K. T., Cheung, C., Hards, K., et al. (2019) · Chemistry - An Asian Journal · doi:10.1002/asia.201801805 · Cited by 12
Shi, K., Zhu, H., Ren, F., et al. (2020) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202001570 · Cited by 12
Metadata
- Authors
- Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., Williams, P., de Chaffoy, D., Huitric, E., Hoffner, S., Cambau, E., Truffot-Pernot, C., Lounis, N., & Jarlier, V.
- Affiliations
- Johnson & Johnson (United Kingdom) (GB)
- Johnson & Johnson Pharmaceutical Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium.
- Corresponding author
- Andries, Koen
- Lounis, Nacer
- Venue
- Science
- Published
- 2005-01-14
- Volume
- 307
- Issue
- 5707
- Pages
- 223-227
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2158658436
- Cited by
- 2,191
- References
- 13
- Citations by year
- 2026: 63 · 2025: 98 · 2024: 103 · 2023: 106 · 2022: 111 · 2021: 98 · 2020: 136 · 2019: 141 · 2018: 102 · 2017: 124 · 2016: 120 · 2015: 129 · 2014: 140 · 2013: 106 · 2012: 102
- FWCI
- 27.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › ATP Synthase and ATPases Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- diarylquinolines, Mycobacterium tuberculosis, tuberculosis drug resistance, ATP synthase inhibition, proton pump, bactericidal activity, combination therapy, isoniazid
- MeSH terms
- Amino Acid Sequence, Animals, Antitubercular Agents, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Drug Therapy, Combination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
